Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?

doi:10.1016/S0140-6736(95)90061-6

The Lancet

Volume 345, Issue 8942, 14 January 1995, Pages 87-90

https://doi.org/10.1016/S0140-6736(95)90061-6 Get rights and content

Abstract

Chromosomal aberrations are characteristic and specific events; the detection of chromosomal abnormalities often provides information on diagnosis and prognosis of disease. Some patients with large-cell anaplastic lymphoma (Ki 1 lymphoma) have the translocation t(2;5) (p23; q35), involving a possible growth-regulating tyrosine kinase. We found this translocation in 11 patients with Hodgkin's disease of nodular sclerosis and mixed-cellularity types. This finding has implications for the understanding of the relation between large-cell anaplastic lymphoma and Hodgkin's disease, diseases with morphological and immunophenotypical similarities. Study of this translocation may help understanding of the origins of cancer and cancer growth. It also allows a more precise definition of Hodgkin's disease and may be used as an indicator for clonality—which has long been sought.

References (18)

A. Ullrich et al.
Signal transduction by receptors with tyrosine kinase activity
Cell
(1990)
Me Kadin
Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin's disease
Lancet
(1985)
I. Anagnostopoulos et al.
Demonstration of monoclonal EBV genomes in Hodgkin's Disease and Ki-1-positive anaplastic large cell lymphoma by combined southern blot and in situ hybridization
Blood
(1989)
Ka MacLennan et al.
Diagnosis and grading of nodular sclerosing Hodgkin's disease: a study of 2100 patients
Int Rev Exp Pathol
(1992)
H. Merz et al.
Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma
Blood
(1991)
M. Jücker et al.
Expression of Interleukin 6 and Interleukin 6 Rezeptor in Hodgkin's disease
Blood
(1991)
P. Fischer et al.
A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade Non Hodgkin's Lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene
Blood
(1988)
C. Fonatsch et al.
Cytogenetic investigations in Hodgkin's disease: Involvement of specific chromosomes in marker formation
Cancer Genet Cytogenet
(1986)

There are more references available in the full text version of this article.

Cited by (105)

Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma
2015, Pathology
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
2009, American Journal of Pathology
Citation Excerpt :
Furthermore, since EML4-ALK proteins (variant 1 and 3) are clearly detectable by immunoblotting and immunohistochemistry in the H2228 and H3122 cell lines,31 weaker activity of EML4 than the NPM1 promoter is unlikely to account for the differences in protein expression in NSCLC when compared with other tumors carrying ALK rearrangements. Finally, as in NSCLC, an ALK fusion transcript (ie, NPM-ALK) without the corresponding fusion protein, was observed in Hodgkin's disease and lymphomas other than ALK-positive ALCL,32–34 whose pathogenesis is thought not to be related to ALK rearrangements. Thus, the role of EML4-ALK in the pathogenesis of NSCLC remains controversial and our findings call for further validation in experimental models fully mimicking EML4-ALK protein expression patterns found in primary NSCLCs.
A fusion gene, echinoderm microtubule associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear. Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls. In cases carrying the fusion transcript, we determined EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunoprecipitation. We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the molecular studies. EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor. Notably, no transcripts were detected in matching tumor samples from these patients. Fluorescence in situ hybridization analysis of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene. None of these cases was found to express the EML4-ALK protein as examined by immunohistochemistry, Western blotting, and immunoprecipitation. The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.
Molecular biology of Hodgkin's lymphoma
2002, Advances in Cancer Research
Hodgkin's lymphoma (HL) is characterized by typical mononucleated Hodgkin and multinucleated Reed-Sternberg cells, which occur at low frequency in a mixed cellular infiltrate in the tumor tissue. Because of the rarity of these cells and their unusual immunophenotype, which is strikingly different from those of all normal hematopoietic cell types, the origin of these cells and their clonality have long been unclear. Single-cell studies of rearranged immunoglobulin genes showed that Hodgkin and Reed-Sternberg (HRS) cells represent clonal tumor-cell populations derived from germinal center B cells. In classical HL, the detection of obviously crippling immunoglobulin gene mutations in a fraction of the cases suggests that HRS cells may derive from germinal center B cells that have lost the capacity to be positively selected by antigen and that normally would have undergone apoptosis. In rare cases, HRS cells represented transformed T lymphocytes. The transforming events involved in malignant transformation of HRS cells are still largely unknown. Constitutive activation of the transcription factor NFκB, which can, for example, be induced through Epstein-Barr virus transformation of HRS cells or destructive somatic mutations of the inhibitor of NFκB, is likely to be a key even in HL pathogenesis. Significant progress has been made in our understanding of the cellular interactions in HL-tissues, which are mainly mediated by a large variety of cytokines and chemokines.
Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease
2001, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Purpose: The aim of this study was to find out the structural chromosomal changes in somatic cells after chemotherapy (CT) with or without radiotherapy (RT).
Methods and Materials: This prospective study included 30 Hodgkin’s disease (HD) patients. The patients of Group I¹ had only MOPP/ABV CT. The patients of Group II² also had irradiation. Group III³ (control group) consisted of healthy subjects without any reported malignant disease. Mutagenetic testing was performed at the time of diagnosis and was repeated immediately after treatment and again 6 months later. The following tests were applied: structural chromosomal aberrations (CA), sister chromatid exchange (SCE) and micronucleus (MN) tests.
Results: Prior to treatment, the chromosome damage in our patients was not higher than that in the control group.
Immediately after the complete treatment, we observed a strong inhibition of the mitotic activity of lymphocytes as well as a significant increase in the frequency of CA, MN and SCE in the Groups I and II. In patients treated by RT, we found statistically significant differences between the Groups I and II in MN (P<0.005) and CA frequencies (P<0.005), and an increased number of dicentrics (P=0.021).
Six months after the complete treatment, the mitotic activity was found to be nearly normal, but chromosome damage occurred. CA and SCE values did not differ much from the values measured immediately after treatment, whereas MN values decreased without returning to the baseline levels. The chromosome damage persisted even 6 months after combined RT and CT. The damage in the genome of individual cells was in some cases even greater than immediately after treatment. The possible risk of neoplastic transformation posed by these heavily damaged cells, if viable, due to the changes in the expression of oncogenes or tumour suppresser genes, is discussed.
ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report
2021, Thoracic Cancer
Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
2019, Clinical Pharmacokinetics

View all citing articles on Scopus

View full text

Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?

Abstract

Cell

Lancet

Blood

Int Rev Exp Pathol

Blood

Blood

Blood

Cancer Genet Cytogenet